

Differentiating the efficacy of tumor necrosis factor inhibitors.

Boulos Haraoui

J Rheumatol 2005;74;3-7

<http://www.jrheum.org/content/74/3>

1. Sign up for TOCs and other alerts  
<http://www.jrheum.org/alerts>
2. Information on Subscriptions  
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints  
[http://jrheum.com/reprints\\_permissions](http://jrheum.com/reprints_permissions)

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

# Differentiating the Efficacy of Tumor Necrosis Factor Inhibitors

BOULOS HARAOUÏ

**ABSTRACT.** Blockade of tumor necrosis factor (TNF) has emerged as one of the most promising therapies in rheumatoid arthritis (RA). Three agents are currently available as specific TNF antagonists, etanercept (Enbrel®), infliximab (Remicade®), and adalimumab (Humira®). Data from noncomparative trials suggest that all 3 agents have comparable therapeutic activity in RA. Etanercept and infliximab have also demonstrated beneficial activity in other inflammatory arthritides [i.e., psoriatic arthritis and ankylosing spondylitis (both agents) and juvenile rheumatoid arthritis (etanercept only)] and inflammatory diseases (i.e., psoriasis and uveitis). Their effects in granulomatous diseases are more variable, with only infliximab demonstrating clear efficacy in the treatment of Crohn's disease, sarcoidosis, and Wegener's vasculitis. In this brief review current efficacy data are summarized and possible explanations for observed clinical differences are explored. (J Rheumatol 2005;32 Suppl 74:3-7)

*Key Indexing Terms:*

TUMOR NECROSIS FACTOR INHIBITORS  
PSORIASIS

RHEUMATOID ARTHRITIS  
CROHN'S DISEASE

The effectiveness of the recombinant fusion protein etanercept and monoclonal antibodies infliximab and adalimumab varies with agent and disease (Table 1). Differences in both the pathophysiology of the diseases and the specific properties of the molecules and their mode of administration likely contribute to these observations.

## TNF INHIBITORS IN INFLAMMATORY ARTHRITIDES

**Rheumatoid arthritis.** All 3 anti-tumor necrosis factor (TNF) agents have demonstrated efficacy in the treatment of RA. Etanercept has shown consistent responses across several clinical trials, alone or in combination with methotrexate (MTX)<sup>1-4</sup>. The overall response rate measured by the American College of Rheumatology criteria for 20% improvement (ACR 20) varied between 59% and 75% for the patients who were treated with etanercept alone at doses of 16 to 25 mg twice weekly. Response rates in trials of combination with MTX were similar, between 71% and 85%, with higher response rates seen in patients naive to MTX. Moreover, the efficacy of etanercept is sustained over time and the rate of secondary failure is low: in the range of 8% over 48 months<sup>5</sup>. Some of these failures are possibly due to changes in the administration of concomitant medications (e.g., MTX, corticosteroids).

The efficacy of infliximab in RA was established in a

large study, the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT), and is supported by considerable clinical experience<sup>6,7</sup>. In the ATTRACT, combination infliximab/MTX regimens were found to be superior to MTX alone at 30 ( $p < 0.001$ ) and at 102 ( $p < 0.05$ ) weeks based on the ACR 20 response criteria. Several infliximab dosage regimens were tested: 3 mg/kg q8 weeks, 3 mg/kg q4 weeks, 10 mg/kg q8 weeks, and 10 mg/kg q4 weeks. All regimens produced similar response rates using ACR 20 criteria at 30, 54, and 102 weeks. Using the more stringent ACR 50 response criteria, the 10 mg/kg regimens were statistically superior to the 3 mg/kg regimens at 54 weeks ( $p < 0.05$ ). There was a slight drop in efficacy with all doses over time, most likely due to primary failures early on (in the first 54 weeks) and secondary failures thereafter. Data from a US infliximab registry ( $n = 1324$ ) indicate that, in the clinic, dose increases are common (~56% of patients at 1.5 years), and about 0.4 mg/kg/year<sup>8</sup>. An audit of infliximab use at a single rheumatology clinic revealed similar findings, with dose increases and/or interval reductions made in 58% of patients continuing therapy beyond 5 infusions or 22 weeks ( $n = 26$ )<sup>9</sup>.

Combination adalimumab/MTX therapy has also been proven effective in the treatment of RA. In the Monoclonal Antibody Adalimumab (D2E7) in Rheumatoid Arthritis (ARMADA) trial ( $n = 271$ ), the addition of adalimumab 20, 40, or 80 mg subcutaneously (SC) every other week to established MTX therapy resulted in significant increases in ACR 20 (48% to 66% vs 14% for adalimumab + MTX vs MTX alone, respectively;  $p \leq 0.05$ ) and ACR 50 response rates (32% to 55% vs 8% for adalimumab + MTX vs MTX alone, respectively;  $p \leq 0.05$ )<sup>10</sup>. In a recent large, 24 week, double-blind, randomized, placebo-controlled safety trial [Safety Trial

*From the Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.*

*Dr. Haraoui is a consultant to Abbott Canada, Amgen Canada, Schering Canada, and Wyeth Canada.*

*B. Haraoui, MD, FRCPC.*

*Address reprint requests to Dr. B. Haraoui, CH de l'Université de Montréal, 1560 Sherbrooke East, Montreal, Québec, Canada H2L 4M1. E-mail: paulharaoui@atglobal.net*

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2005. All rights reserved.

Haraoui: Efficacy of TNF inhibitors

3

Table 1. Efficacy of TNF inhibitors.

Disease	Etanercept	Infliximab	Adalimumab
Inflammatory arthritis			
Rheumatoid arthritis	+	+	+
Juvenile arthritis	+	ND	ND
Ankylosing spondylitis	+	+	
Psoriatic arthritis	+	+	
Other rheumatic diseases			
Sjögren's syndrome	ND		
Scleroderma			
Polymyositis/dermatomyositis			
Granulomatous diseases			
Crohn's disease	-	+	
Sarcoid	-	+	
Wegener's vasculitis	±	+	
Other inflammatory diseases			
Psoriasis	+	+	
Uveitis	+	+	

+: proven efficacy; -: no efficacy; ±: partial efficacy; ND: not studied in that indication; blank fields indicate no data available.

of Adalimumab in Rheumatoid Arthritis (STAR); n = 636], the addition of adalimumab 40 mg SC once every other week to standard therapy [traditional disease modifying antirheumatic drugs (DMARD), low-dose corticosteroids, and/or analgesics] in patients with active RA was well tolerated<sup>11</sup>. Patients in the adalimumab plus standard therapy group achieved superior ACR 20 (52.8% vs 34.9%), ACR 50 (28.9% vs 11.3%), and ACR 70 (14.8% vs 3.5%) responses compared with placebo at Week 24 (p ≤ 0.001 vs placebo for all comparisons); significant differences between groups were evident as early as Week 2.

Data from several small series and case reports indicate that patients who do not respond to etanercept or infliximab may benefit from switching to the other agent<sup>12-14</sup>. Several explanations for this phenomenon have been proposed, including concomitant changes in comedications, interpatient variability in pharmacokinetic parameters, antibody formation, and/or disease characteristics. It is also possible that there exists a subset of patients who have disease driven by different cytokines (such as lymphotoxin) rather than TNF- $\alpha$ <sup>15</sup>. Lymphotoxin is known to play a role in juvenile rheumatoid arthritis (JRA)<sup>16,17</sup>, but its role in RA has not been established. Because etanercept, but not infliximab, binds lymphotoxin, etanercept would theoretically be more effective in this subset of patients<sup>18,19</sup>.

Data from the Canadian Biologic Observational Switchover Study (CAN-BOSS; n = 25) (Haraoui, in press) indicate that the efficacy of etanercept in patients who have previously received infliximab is similar to that observed in other etanercept-naïve patients (ACR 20 and ACR 50 response rates of 58.3% and 20.8% at Week 12, respectively). Notably, a large proportion of patients who were switched from infliximab to etanercept therapy had detectable levels of human anti-chimeric antibodies (HACA), with an average titer of 9.5 to 12.2  $\mu$ g/ml.

The clinical impact of HACA in RA remains to be established. The reported incidence of HACA in the ATTRACT study was 8.5%; however, no difference in ACR response based on antibody status was detected in the subgroup of patients who completed 2 years of the study<sup>20</sup>. This estimation of the incidence and impact of HACA must be interpreted with caution, as the HACA status of the majority of patients was "indeterminate" due to the presence of detectable levels of circulating infliximab, which prevent the accurate measurement of HACA. Data regarding any relationship between HACA and infusion reactions in ATTRACT have not been published.

Data from patients with Crohn's disease (CD) are clearer. In the ACCENT I trial (A Crohn's Disease Clinical Trial Evaluating Infliximab in a New Longterm Treatment Regimen; n = 573 patients with CD), infusion reactions were more common among patients positive for antibodies to infliximab (16%) than among those who were negative or indeterminate (8% and 3%, respectively)<sup>21</sup>. In a separate cohort of 125 patients with CD, a positive relationship between antibody concentrations and infusion reactions was observed [median concentration (95% confidence interval, CI), 20.1 (3.0-22.6)  $\mu$ g/ml vs 3.2 (1.6-4.9)  $\mu$ g/ml; p < 0.001] as was a negative relationship between antibody titers and duration of response (35 days vs 70 days among patients with titers  $\geq$  8 and < 8  $\mu$ g/ml, respectively)<sup>22</sup>.

**Juvenile rheumatoid arthritis.** Only etanercept has demonstrated efficacy in the treatment of JRA in a clinical trial<sup>23,24</sup>. This trial consisted of 3 phases: a 3 month open-label phase in which all patients (n = 69) were treated with etanercept [0.4 mg/kg SC 2 times weekly (up to maximum of 25 mg)], a 4 month randomized, double-blind phase in which half of the patients were switched to placebo, and an open-label extension. At Month 3, clini-

cal benefit was observed in 74% of patients. At Month 7, 80% of patients treated with etanercept and 35% of patients switched to placebo for 4 months achieved the JRA 30% definition of improvement ( $p < 0.01$ ). Among those who switched from etanercept to placebo, clinical deterioration was evident within 1 week (median time to disease flare in the placebo group, 28 days). Eighty-three percent of patients completed 2 years of study and were included in an interim analysis of longterm efficacy and safety. At the end of 2 years, 69%, 67%, and 57% of patients demonstrated 30%, 50%, and 70% improvement, respectively. Patients treated with placebo for 4 months rapidly regained clinical benefit, and 77%, 77%, and 68% demonstrated 30%, 50%, and 70% improvements, respectively, at the end of 2 years. Testing for ANA and anti-dsDNA antibodies at baseline, 6, and 12 months showed no evidence of the development of new autoantibodies.

Neither infliximab nor adalimumab has been studied in double-blind, placebo-controlled clinical trials in patients with JRA. Data for infliximab from one open-label study ( $n = 24$ ) indicate a high failure rate among JRA patients<sup>25</sup>. By 2 years, 5/24 patients had stopped therapy for lack of efficacy and 7/24 for adverse events during the infusions. Nine had completed 2 years of therapy at the time of the report. Among these, response was rapid (evident after the first infusion) and sustained. These data suggest that the pathogenesis of JRA differs from that of RA. Higher levels of lymphotoxin may explain the lesser response seen with infliximab compared with etanercept.

**Psoriatic arthritis.** Etanercept and infliximab appear to have similar efficacy in the treatment of psoriatic arthritis (PsA). In a 12 week randomized, double-blind, placebo-controlled trial of 60 patients with PsA, etanercept 25 mg SC twice weekly was superior to placebo, with respective response rates at 12 weeks using both the Psoriatic Arthritis Response Criteria (PsARC) of 87% vs 23% and the ACR 20 of 73% vs 13%<sup>26</sup>. Continued administration for periods of up to 106 weeks has been shown to be safe and effective for the maintenance of beneficial effects<sup>27</sup>.

The efficacy of infliximab in PsA has been evaluated in a 16 week double-blind randomized placebo-controlled trial of 102 patients<sup>28</sup>. At 16 weeks, the ACR 20 response was at 69% compared to 8% for the placebo group. The clinical response was maintained at Week 50 of the open-label extension, with an ACR 20 response of 72%.

Etanercept and infliximab also appear to have similar effects on psoriatic skin disease. In a subset of evaluable patients participating in the initial etanercept trial described above ( $n = 19$ ), 75% of patients in the etanercept group and 0% of patients in the placebo group demonstrated 75% improvement on the Psoriasis Area and Severity Index (PASI). In a larger ( $n = 672$ ) 24-week fixed-dose study, low (25 mg once weekly), medium (25

mg twice weekly), and high (50 mg twice weekly) doses of etanercept produced significant improvement in skin disease compared with placebo by Week 12 (4%, 14%, 34%, and 49% of patients had improvement of  $\geq 75\%$  on the PASI in the placebo and etanercept low-, medium-, and high-dose groups, respectively;  $p < 0.001$  vs placebo)<sup>29</sup>. Response rates were even higher at Week 24 (25%, 44%, and 59%, respectively).

Similarly, PASI and National Psoriasis Foundation psoriasis scores (NPF-PS) improved following the repeated administration (3 doses) of infliximab 5 mg/kg or 10 mg/kg, but not placebo, in a single randomized trial<sup>30,31</sup>. Improvement of 75% on the PASI was observed in 9/11, 8/11, and 2/11 patients in the infliximab 5 mg/kg, 10 mg/kg, and placebo groups, respectively. Significantly more patients in the infliximab groups (9/11 and 10/11) demonstrated good or excellent responses or clearing on the NPF-PS than in the placebo group (2/11;  $p < 0.01$ ).

**Ankylosing spondylitis.** Etanercept and infliximab have demonstrated similar efficacy in the treatment of ankylosing spondylitis (AS). In a 4 month randomized, double-blind, placebo-controlled trial in patients with active, inflammatory AS ( $n = 40$ ), the administration of etanercept 25 mg SC twice weekly was associated with significant response (80% of patients demonstrated  $\geq 20\%$  improvement in at least 3 of 5 measures of disease activity, including duration of morning stiffness and/or degree of nocturnal spinal pain) compared to 30% in the placebo group<sup>32</sup>.

In a separate randomized, double-blind, placebo-controlled study ( $n = 30$  patients with active AS), 57% of patients treated with etanercept 25 mg SQ twice weekly for 6 weeks and 6% of patients who received placebo demonstrated  $\geq 50\%$  reduction in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores ( $p = 0.004$ )<sup>33</sup>. After switching from placebo to etanercept at Week 7, 56% of patients achieved a BASDAI 50 response.

Infliximab also reduces symptoms of AS. In a randomized, double-blind, placebo-controlled clinical study ( $n = 70$ ), the administration of infliximab 5 mg/kg IV or placebo at Weeks 0, 2, and 6 resulted in 50% reduction on the BASDAI at 12 weeks in 53% vs 9% of patients in the infliximab and placebo treatment groups, respectively ( $p < 0.001$ )<sup>34</sup>. Efficacy was maintained longterm in a 54-week open-label extension (47% demonstrated  $\geq 50\%$  response on the BASDAI at Week 54)<sup>35</sup>.

## TNF INHIBITORS IN GRANULOMATOUS DISEASES

Etanercept and infliximab have differing effects in granulomatous diseases, such as Crohn's disease, sarcoidosis, and Wegener's vasculitis. Infliximab appears to be more effective in the treatment of these conditions than etanercept. It has been shown to rapidly induce remission in

moderate to severe, treatment-resistant Crohn's disease (n = 108), with 61% and 65% of patients demonstrating clinical response 2 weeks and 4 weeks after a single infliximab infusion of 5 mg/kg, 10 mg/kg, or 20 mg/kg<sup>36</sup>. In a separate study, clinical response was maintained in 62% of patients treated with infliximab 10 mg/kg every 8 weeks for 36 weeks (n = 73)<sup>37</sup>. In contrast, clinical response following administration of etanercept 25 mg SC twice weekly for 8 weeks was not statistically different from placebo<sup>38</sup>.

Several hypotheses have been put forward to explain this discrepancy. Etanercept and infliximab have different binding characteristics, with infliximab binding to both soluble and membrane-bound TNF and etanercept binding primarily to soluble TNF<sup>39</sup>. These differences in binding may manifest as differing effects on complement activation and apoptosis. *In vitro*, infliximab may lyse TNF-producing cells via activation of complement<sup>40</sup>. It also appears to induce apoptosis of immune/inflammatory cells, a process that is deficient in patients with active Crohn's disease<sup>41,42</sup>.

Etanercept and infliximab also have different pharmacokinetic profiles that may influence their activity. Because infliximab is administered as bolus injections every 4 to 8 weeks, there is great variability in concentrations over time (high peaks separated by periods of low levels). High peaks could contribute to greater tissue penetration, which could be more relevant in certain diseases than maintaining stable concentrations with little variation, as observed with etanercept, which is administered SC twice weekly.

## SUMMARY

The TNF inhibitors etanercept, infliximab, and adalimumab have similar efficacy profiles in RA. However, differences exist between etanercept and infliximab in other disease states such as JRA or the granulomatous diseases. Differences in the efficacy profiles of these drugs are likely related to the pathophysiology of the diseases (e.g., role of lymphotoxin) as well as drug characteristics (e.g., dosing, pharmacokinetics, immunogenicity, ability to block lymphotoxin or fix complement, or propensity to induce apoptosis). Additional studies are needed to better define these differences and optimize the clinical utilization of these agents.

## REFERENCES

1. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med* 1997;337:141-7.
2. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. *Ann Intern Med* 1999;130:478-86.
3. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253-9.
4. Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;363:675-81.
5. Klareskog L, Moreland LM, Cohen SB, Sanda M, Burge DJ. Global safety and efficacy of up to five years of etanercept therapy [abstract]. *Arthritis Rheum* 2001;44 Suppl:S77.
6. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. *Lancet* 1999;354:1932-9.
7. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. *Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med* 2000;343:1594-602.
8. Wolfe F, Stern R. Infliximab dose and clinical status in 1,248 RA patients seen in rheumatology clinical practice [abstract]. *Arthritis Rheum* 2003;48 Suppl:S328.
9. Fitzcharles M-A, Clayton D, Ménard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. *J Rheumatol* 2002;29:2525-30.
10. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum* 2003;48:35-45.
11. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol* 2003;30:2563-71.
12. Brocq O, Plubel Y, Breuil V, et al. Etanercept- infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNF alpha [French]. *Presse Med* 2002;31:1836-9.
13. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab when etanercept has failed or vice versa: data from the STURE registry, showing that switching tumor necrosis factor alpha blockers can make sense. *Ann Rheum Dis* 2003;62:1195-8.
14. Ang HTS, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other TNF alpha antagonists in patients with rheumatoid arthritis. *J Rheumatol* 2003;30:2315-8.
15. Buch MH, Seto Y, Bingham SJ, et al. Understanding nonresponse to infliximab: subtypes of nonresponse; its importance in the pathogenesis of rheumatoid arthritis [abstract]. *Arthritis Rheum* 2003;48 Suppl:S701.
16. Grom A, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. *Arthritis Rheum* 1996;39:1703-10.
17. Eberhard BA, Laxer RM, Andersson U, Silverman ED. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. *Clin Exp Immunol* 1994;96:260-6.
18. Enbrel® (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; October 2003.
19. Remicade® (infliximab) prescribing information. Malvern, PA: Centocor, Inc; September 2003.
20. Wagner CL, St. Clair EW, Han C, Ford J, Schantz A, Maini RN. Effects of antibodies to infliximab on ACR response in patients with rheumatoid arthritis in the ATTRACT study [abstract].

Presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology, June 2002, Stockholm, Sweden. Internet. [Cited November 22, 2004.] Available from: <http://www.eular.org>

21. Hanauer SB, Feagan BF, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. *Lancet* 2002;359:1541-9.
22. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *N Engl J Med* 2003;348:601-8.
23. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *N Engl J Med* 2000;342:763-9.
24. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2003;48:218-26.
25. Gerloni V, Lurati A, Gattinara M, Pontikaki I, Fantini F. Efficacy of infusions of an anti-TNF antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis: results of a two year open label prospective study [abstract]. *Arthritis Rheum* 2003;48 Suppl:S92.
26. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet* 2000;356:385-90.
27. Mease PJ, Ruderman EM, Kivitz AJ, et al. Continued efficacy and safety of etanercept (Enbrel®) in patients with psoriatic arthritis and psoriasis [abstract]. *Arthritis Rheum* 2003;48 Suppl:S169.
28. Antoni C, Kavanaugh A, Kirkham B, et al. The one year results of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) [abstract]. *Arthritis Rheum* 2003;48 Suppl:S265.
29. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* 2003;349:2014-22.
30. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. *Lancet* 2001;357:1842-7.
31. Gottlieb AB, Chaudhari U, Romano P, et al. Infliximab monotherapy in the treatment of plaque-type psoriasis. *Arthritis Rheum* 2001;44 Suppl:S383.
32. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med* 2002;346:1349-56.
33. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum* 2003;48:1667-75.
34. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet* 2002;359:1187-93.
35. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. *Arthritis Rheum* 2003;48:2224-33.
36. Targan SR, Hanauer SB, Van Deventer SJH. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. *N Engl J Med* 1997;337:1029-35.
37. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. *Gastroenterology* 1999;117:761-9.
38. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. *Gastroenterology* 2001;121:1088-94.
39. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. *J Pharmacol Exper Ther* 2002;301:418-26.
40. Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. *Am J Med Sci* 2003;325:75-92.
41. Lügering A, Schmidt M, Lügering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. *Gastroenterology* 2001;121:1145-57.
42. Boirivant M, Marini M, Di Felice G, et al. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. *Gastroenterology* 1999;116:557-65.